^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    golidocitinib (DZD4205)

    i
    Other names: DZD4205, AZD-4205, AZD 4205, AZD4205, DZD-4205
    Company:
    Dizal Pharma
    Drug class:
    JAK1 inhibitor
    Related drugs:
    16d
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) (clinicaltrials.gov)
    P3, N=218, Recruiting, Dizal Pharmaceuticals
    New P3 trial
    |
    gemcitabine • Epidaza (chidamide) • Beleodaq (belinostat) • Folotyn (pralatrexate) • golidocitinib (DZD4205)
    1m
    Prospective, Multicenter, Single-Arm Clinical Study of Golidocitinib Combined with CMOP Regimen in the Treatment of Previously Untreated Young Patients with Peripheral T-Cell Lymphoma (PTCL) (ChiCTR2500109697)
    P=N/A, N=45, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University
    New trial
    |
    golidocitinib (DZD4205)
    1m
    A prospective, single-arm,multicenter center clinical study of JAK1 inhibitor Golidocitinib combined with steroid as first-line treatment for chronic graft-versus-host disease patients with high risk of steroid therapy failure. (ChiCTR2500108541)
    P4, N=40, Not yet recruiting, The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital of Army Medical University); The Second Affiliated Hospital of Army Medica
    New P4 trial
    |
    prednisone • golidocitinib (DZD4205)
    2ms
    Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=48, Not yet recruiting, Ruijin Hospital
    New P1/2 trial
    |
    Tazverik (tazemetostat) • Itari (linperlisib) • golidocitinib (DZD4205)
    2ms
    An Exploratory Study of Golidocitinib in Adult Patients With ITP (clinicaltrials.gov)
    P1/2, N=138, Not yet recruiting, Peking University People's Hospital
    New P1/2 trial
    |
    golidocitinib (DZD4205)
    3ms
    Golidocitinib was used for the first time to treat refractory NK-Large Granular lymphocytic leukemia with a STAT3 mutation, accompanied by hemolytic anemia: a case report. (PubMed, Front Immunol)
    Despite receiving various treatments such as methotrexate, cyclosporin, cyclophosphamide, and thalidomide, the patient exhibited treatment refractoriness. This case highlights the clinical relevance of golidocitinib in developing novel therapeutic strategies for NK-LGLL. Moreover, this treatment option presents the potential as either a bridging therapy or alternative to allo-HSCT.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    STAT3 mutation
    |
    cyclophosphamide • methotrexate • thalidomide • golidocitinib (DZD4205)
    4ms
    JACKPOT38: Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    golidocitinib (DZD4205)
    4ms
    Phase I/II Study Evaluating the Safety and Efficacy of Golidocitinib Combined with CHOP as First-Line Treatment in Patients with Peripheral T-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Clinical Trial (ChiCTR2500107078)
    P4, N=59, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P4 trial
    |
    ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • GZMB (Granzyme B) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule)
    |
    ALK positive • TNFRSF8 expression • ALK negative
    |
    golidocitinib (DZD4205)
    4ms
    Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or GemOx in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=101, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    oxaliplatin • golidocitinib (DZD4205) • Duoenda (mitoxantrone liposomal)
    4ms
    Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma. (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    azacitidine • Epidaza (chidamide) • golidocitinib (DZD4205)
    5ms
    A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) (clinicaltrials.gov)
    P2, N=90, Recruiting, Dizal Pharmaceuticals | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Zegfrovy (sunvozertinib) • golidocitinib (DZD4205)
    5ms
    AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) (clinicaltrials.gov)
    P2, N=48, Completed, Dizal Pharmaceuticals | Active, not recruiting --> Completed | N=130 --> 48 | Trial completion date: Mar 2026 --> Mar 2025
    Trial completion • Enrollment change • Trial completion date
    |
    golidocitinib (DZD4205)